$68.31
0.01% today
Nasdaq, Apr 03, 06:44 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Target price 2025 - Analyst rating & recommendation

Biomarin Pharmaceutical Classifications & Recommendation:

Buy
81%
Hold
19%

Biomarin Pharmaceutical Price Target

Target Price $97.73
Price $68.32
Potential
Number of Estimates 26
26 Analysts have issued a price target Biomarin Pharmaceutical 2026 . The average Biomarin Pharmaceutical target price is $97.73. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 31 analysts: 25 Analysts recommend Biomarin Pharmaceutical to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Biomarin Pharmaceutical stock has an average upside potential 2026 of . Most analysts recommend the Biomarin Pharmaceutical stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 2.84 3.14
17.35% 10.58%
EBITDA Margin 22.06% 27.94%
78.58% 26.67%
Net Margin 14.85% 19.26%
114.00% 29.71%

26 Analysts have issued a sales forecast Biomarin Pharmaceutical 2025 . The average Biomarin Pharmaceutical sales estimate is

$3.1b
Unlock
. This is
10.58% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$3.2b 12.55%
Unlock
, the lowest is
$3.0b 7.29%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $2.8b 17.35%
2025
$3.1b 10.58%
Unlock
2026
$3.4b 9.85%
Unlock
2027
$3.7b 8.36%
Unlock
2028
$3.9b 5.53%
Unlock
2029
$4.1b 4.24%
Unlock

6 Analysts have issued an Biomarin Pharmaceutical EBITDA forecast 2025. The average Biomarin Pharmaceutical EBITDA estimate is

$877m
Unlock
. This is
53.42% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$970m 69.63%
Unlock
, the lowest is
$821m 43.53%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $626m 109.56%
2025
$877m 40.05%
Unlock
2026
$1.1b 29.16%
Unlock
2027
$1.4b 19.30%
Unlock
2028
$1.7b 23.15%
Unlock
2029
$1.8b 10.12%
Unlock

EBITDA Margin

2024 22.06% 78.58%
2025
27.94% 26.67%
Unlock
2026
32.85% 17.57%
Unlock
2027
36.16% 10.08%
Unlock
2028
42.20% 16.70%
Unlock
2029
44.58% 5.64%
Unlock

19 Biomarin Pharmaceutical Analysts have issued a net profit forecast 2025. The average Biomarin Pharmaceutical net profit estimate is

$605m
Unlock
. This is
44.09% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$687m 63.64%
Unlock
, the lowest is
$427m 1.82%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $422m 151.14%
2025
$605m 43.44%
Unlock
2026
$787m 30.19%
Unlock
2027
$951m 20.78%
Unlock
2028
$1.2b 22.97%
Unlock
2029
$1.3b 11.28%
Unlock

Net Margin

2024 14.85% 114.00%
2025
19.26% 29.71%
Unlock
2026
22.83% 18.54%
Unlock
2027
25.44% 11.43%
Unlock
2028
29.65% 16.55%
Unlock
2029
31.65% 6.75%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 2.21 3.17
151.14% 43.44%
P/E 21.55
EV/Sales 4.00

19 Analysts have issued a Biomarin Pharmaceutical forecast for earnings per share. The average Biomarin Pharmaceutical EPS is

$3.17
Unlock
. This is
44.09% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$3.60 63.64%
Unlock
, the lowest is
$2.24 1.82%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $2.21 151.14%
2025
$3.17 43.44%
Unlock
2026
$4.13 30.28%
Unlock
2027
$4.98 20.58%
Unlock
2028
$6.13 23.09%
Unlock
2029
$6.82 11.26%
Unlock

P/E ratio

Current 31.06 69.02%
2025
21.55 30.62%
Unlock
2026
16.55 23.20%
Unlock
2027
13.71 17.16%
Unlock
2028
11.15 18.67%
Unlock
2029
10.02 10.13%
Unlock

Based on analysts' sales estimates for 2025, the Biomarin Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.42 35.38%
2025
4.00 9.59%
Unlock
2026
3.64 8.97%
Unlock
2027
3.36 7.71%
Unlock
2028
3.18 5.24%
Unlock
2029
3.05 4.07%
Unlock

P/S ratio

Current 4.59 32.60%
2025
4.15 9.56%
Unlock
2026
3.78 8.97%
Unlock
2027
3.49 7.71%
Unlock
2028
3.31 5.24%
Unlock
2029
3.17 4.07%
Unlock

Current Biomarin Pharmaceutical Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Oppenheimer
Locked
Locked
Locked Feb 24 2025
Cantor Fitzgerald
Locked
Locked
Locked Feb 20 2025
B of A Securities
Locked
Locked
Locked Feb 20 2025
RBC Capital
Locked
Locked
Locked Feb 20 2025
Citigroup
Locked
Locked
Locked Feb 20 2025
Scotiabank
Locked
Locked
Locked Feb 20 2025
Piper Sandler
Locked
Locked
Locked Feb 20 2025
Analyst Rating Date
Locked
Oppenheimer:
Locked
Locked
Feb 24 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Feb 20 2025
Locked
B of A Securities:
Locked
Locked
Feb 20 2025
Locked
RBC Capital:
Locked
Locked
Feb 20 2025
Locked
Citigroup:
Locked
Locked
Feb 20 2025
Locked
Scotiabank:
Locked
Locked
Feb 20 2025
Locked
Piper Sandler:
Locked
Locked
Feb 20 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today